Acute Pain - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 192 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Pain - Pipeline Review, H1 2015', provides an overview of the Acute Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Pain Overview 9
Therapeutics Development 10
Pipeline Products for Acute Pain - Overview 10
Pipeline Products for Acute Pain - Comparative Analysis 11
Acute Pain - Therapeutics under Development by Companies 12
Acute Pain - Therapeutics under Investigation by Universities/Institutes 16
Acute Pain - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Acute Pain - Products under Development by Companies 21
Acute Pain - Products under Investigation by Universities/Institutes 26
Acute Pain - Companies Involved in Therapeutics Development 27
A. Menarini Industrie Farmaceutiche Riunite Srl 27
AcelRx Pharmaceuticals, Inc. 28
Adynxx, Inc. 29
AnaBios Corporation 30
Anavex Life Sciences Corp. 31
AngioChem Inc. 32
Antibe Therapeutics, Inc. 33
Cara Therapeutics, Inc. 34
Charleston Laboratories, Inc. 35
ChironWells GmbH 36
Cytogel Pharma, LLC 37
Glenmark Pharmaceuticals Ltd. 38
Grunenthal GmbH 39
Iroko Pharmaceuticals, LLC 40
KemPharm, Inc. 41
Kineta, Inc. 42
Laboratorios Del Dr. Esteve S.A. 43
Mallinckrodt plc 44
MEDRx Co., Ltd. 45
Merck & Co., Inc. 46
Nanomerics Ltd 47
Nektar Therapeutics 48
Nuvo Research Inc. 49
Orbis Biosciences, Inc. 50
Pacira Pharmaceuticals, Inc. 51
Paladin Labs Inc. 52
Rottapharm SpA 53
Santen Pharmaceutical Co., Ltd. 54
Sigma-Tau S.p.A. 55
Syntrix Biosystems, Inc. 56
Thar Pharmaceuticals, Inc. 57
Trevena, Inc. 58
Yungjin Pharm Ind. Co., Ltd. 59
Acute Pain - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 65
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
(acetaminophen + tramadol hydrochloride) - Drug Profile 72
(acetaminophen + tramadol hydrochloride) SR - Drug Profile 74
(benzhydrocodone hydrochloride + acetaminophen) - Drug Profile 75
(celecoxib + tramadol hydrochloride) - Drug Profile 76
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 77
(etodolac + lidocaine) - Drug Profile 78
(etoricoxib + tizanidine) - Drug Profile 80
(hydrocodone + acetaminophen) ER - Drug Profile 81
(lidocaine + tetracaine) - Drug Profile 82
AAT-008 - Drug Profile 84
AAT-076 - Drug Profile 85
ANAVEX-1037 - Drug Profile 86
ANAVEX-1066 - Drug Profile 87
ANAVEX-1067 - Drug Profile 88
ANAVEX-1519 - Drug Profile 89
ANG-2002 - Drug Profile 90
ARX-01 - Drug Profile 91
ARX-04 - Drug Profile 94
ATB-352 - Drug Profile 95
AYX-1 - Drug Profile 96
BBI-11008 - Drug Profile 97
celecoxib nanoformulation - Drug Profile 98
CL-108 - Drug Profile 99
CLH-10 - Drug Profile 100
CLH-5 - Drug Profile 101
CMX-020 - Drug Profile 102
conolidine - Drug Profile 103
CR-4056 - Drug Profile 104
CR-845 - Drug Profile 105
Cyt-1010 - Drug Profile 107
DepoNSAID ER - Drug Profile 109
E-52862 - Drug Profile 110
ET-1 - Drug Profile 112
FY-101C - Drug Profile 113
FY-103B - Drug Profile 114
GIBH-1014 - Drug Profile 115
grapiprant - Drug Profile 116
GRC-27864 - Drug Profile 118
HS-731 - Drug Profile 119
ibuprofen - Drug Profile 120
ibuprofen nanoformulation - Drug Profile 121
ketamine hydrochloride - Drug Profile 122
lidocaine - Drug Profile 123
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile 124
NKTR-192 - Drug Profile 125
NKTR-196 - Drug Profile 126
NM-0127 - Drug Profile 127
Omnitram - Drug Profile 128
prednisone - Drug Profile 129
Prostatic Acid Phosphatase - Drug Profile 130
RO-656570 - Drug Profile 131
SA-14867 - Drug Profile 132
Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder - Drug Profile 133
Small Molecules to Block Nav 1.7 for Pain - Drug Profile 134
Small Molecules to Block Nav 1.8 for Pain - Drug Profile 135
ST-4070 - Drug Profile 136
T-109 - Drug Profile 137
tapentadol hydrochloride - Drug Profile 138
TRV-130 - Drug Profile 139
TRV-734 - Drug Profile 141
U-2902 - Drug Profile 142
VPX-595 - Drug Profile 143
X-0002 - Drug Profile 144
ZEP-3 - Drug Profile 146
Acute Pain - Recent Pipeline Updates 148
Acute Pain - Dormant Projects 171
Acute Pain - Discontinued Products 177
Acute Pain - Product Development Milestones 179
Featured News & Press Releases 179
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188

List of Tables
Number of Products under Development for Acute Pain, H1 2015 14
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Late Stage Development, H1 2015 21
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Development, H1 2015 23
Comparative Analysis by Unknown Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Development by Companies, H1 2015 (Contd..4) 29
Products under Investigation by Universities/Institutes, H1 2015 30
Acute Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 31
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2015 32
Acute Pain - Pipeline by Adynxx, Inc., H1 2015 33
Acute Pain - Pipeline by AnaBios Corporation, H1 2015 34
Acute Pain - Pipeline by Anavex Life Sciences Corp., H1 2015 35
Acute Pain - Pipeline by AngioChem Inc., H1 2015 36
Acute Pain - Pipeline by Antibe Therapeutics, Inc., H1 2015 37
Acute Pain - Pipeline by Cara Therapeutics, Inc., H1 2015 38
Acute Pain - Pipeline by Charleston Laboratories, Inc., H1 2015 39
Acute Pain - Pipeline by ChironWells GmbH, H1 2015 40
Acute Pain - Pipeline by Cytogel Pharma, LLC, H1 2015 41
Acute Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 42
Acute Pain - Pipeline by Grunenthal GmbH, H1 2015 43
Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2015 44
Acute Pain - Pipeline by KemPharm, Inc., H1 2015 45
Acute Pain - Pipeline by Kineta, Inc., H1 2015 46
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 47
Acute Pain - Pipeline by Mallinckrodt plc, H1 2015 48
Acute Pain - Pipeline by MEDRx Co., Ltd., H1 2015 49
Acute Pain - Pipeline by Merck & Co., Inc., H1 2015 50
Acute Pain - Pipeline by Nanomerics Ltd, H1 2015 51
Acute Pain - Pipeline by Nektar Therapeutics, H1 2015 52
Acute Pain - Pipeline by Nuvo Research Inc., H1 2015 53
Acute Pain - Pipeline by Orbis Biosciences, Inc., H1 2015 54
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2015 55
Acute Pain - Pipeline by Paladin Labs Inc., H1 2015 56
Acute Pain - Pipeline by Rottapharm SpA, H1 2015 57
Acute Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 58
Acute Pain - Pipeline by Sigma-Tau S.p.A., H1 2015 59
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H1 2015 60
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2015 61
Acute Pain - Pipeline by Trevena, Inc., H1 2015 62
Acute Pain - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 63
Assessment by Monotherapy Products, H1 2015 64
Assessment by Combination Products, H1 2015 65
Number of Products by Stage and Target, H1 2015 67
Number of Products by Stage and Mechanism of Action, H1 2015 70
Number of Products by Stage and Route of Administration, H1 2015 73
Number of Products by Stage and Molecule Type, H1 2015 75
Acute Pain Therapeutics - Recent Pipeline Updates, H1 2015 152
Acute Pain - Dormant Projects, H1 2015 175
Acute Pain - Dormant Projects (Contd..1), H1 2015 176
Acute Pain - Dormant Projects (Contd..2), H1 2015 177
Acute Pain - Dormant Projects (Contd..3), H1 2015 178
Acute Pain - Dormant Projects (Contd..4), H1 2015 179
Acute Pain - Dormant Projects (Contd..5), H1 2015 180
Acute Pain - Discontinued Products, H1 2015 181
Acute Pain - Discontinued Products (Contd..1), H1 2015 182